Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Reference45 articles.
1. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged ≥18 years—United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65(42):1166–1169.
2. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383–1395.
3. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392-400.e393.
4. Beaugerie L, Kirchgesner J. Balancing benefit vs risk of Immunosuppressive therapy for individual patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17(3):370–379.
5. Severs M, Oldenburg B, van Bodegraven AA, Siersema PD, Mangen MJ, Colitis ioCsa. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis 2017;11(3):289–296.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献